Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1294790 | 1.00 | CMA1 (0.34) | CMA1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL1294380 | 0.91 | CMA1 (0.42) | CMA1TSHR | |
| SCHEMBL1294381 | 0.91 | CMA1 (0.42) | CMA1TSHR | |
| SCHEMBL1295200 | 0.90 | CMA1 (0.41) | CMA1ALDH1A1MAPT | |
| SCHEMBL1295203 | 0.90 | CMA1 (0.41) | CMA1ALDH1A1MAPT | |
| SCHEMBL2315129 | 0.88 | CMA1 (0.36) | CMA1KDM4EALDH1A1MAPTPKM | |
| SCHEMBL2315122 | 0.88 | CMA1 (0.36) | CMA1KDM4EALDH1A1MAPTPKM | |
| SCHEMBL2313567 | 0.88 | CMA1 (0.34) | CMA1ALDH1A1MAPTHSD17B10TSHR | |
| SCHEMBL1295114 | 0.86 | CMA1 (0.41) | CMA1ALDH1A1MAPT | |
| SCHEMBL1294398 | 0.86 | KDM4E (0.34) | KDM4EALDH1A1MAPTHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062056-B2 | Aza-benzimidazolone Chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| EP-2364313-B1 | AZA-BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-01-08 | — | — | EP | disclosed |
| US-20110269780-A1 | AZA-BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2364313-A1 | AZA-BENZIMIDAZOLONE CHYMASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010030500-A1 | AZA-BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269780-A1 | AZA-BENZIMIDAZOLONE CHYMASE INHIBITORS | CMA1, CPA3, SERPINB1 | CMA1 1/4885KDM4E 763/4885ALDH1A1 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.